Biogen Idec to present MS data at AAN conference
7 April 2010 00:00 in Pharmaceutical Company Product News
Biogen Idec is to attend the American Academy of Neurology's (AAN's) 62nd Annual Meeting this month in order to present new data on multiple sclerosis (MS) treatments.
The company, which is responsible for MS brands such as Tysabri and Avonex, will be looking to discuss a number of commercially available drugs, as well as several promising new compounds.
In addition to highlighting the advantages of its two established MS treatments, the firm will discuss prolonged-release fampridine, a compound designed to improve walking ability among sufferers.
Results from studies into drugs such as dimethyl fumarate, PEGylated Interferon beta-1a and daclizumab will also be presented.
Dr Alfred Sandrock, senior vice-president of neurology research and development at Biogen Idec, said: "Our innovative pipeline of MS product candidates is a testament to our commitment to the MS community."
Last month, the company commenced enrolment for a new phase IIIb study of Tysabri intended to evaluate the advantages of switching to the drug from Copaxone and Rebif.
Other news stories from 07/04/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency